New gene therapy SNUG01 targets ALS in first human trial
Disease control
Not yet recruiting
This early-stage study tests a new gene therapy called SNUG01 in 21 adults with ALS. The main goal is to check if it is safe and tolerable, and to see early signs of whether it might slow the disease. Participants receive the treatment via a spinal injection and are closely monit…
Phase: PHASE1, PHASE2 • Sponsor: SineuGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 11:17 UTC